Janney Montgomery Scott LLC Sells 4,294 Shares of DexCom, Inc. (NASDAQ:DXCM)

Janney Montgomery Scott LLC cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 11.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,871 shares of the medical device company’s stock after selling 4,294 shares during the quarter. Janney Montgomery Scott LLC’s holdings in DexCom were worth $3,954,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Valley National Advisers Inc. raised its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. MV Capital Management Inc. lifted its position in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Smithfield Trust Co boosted its holdings in DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Washington Trust Advisors Inc. grew its position in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares in the last quarter. Finally, NBC Securities Inc. purchased a new stake in DexCom in the 3rd quarter valued at about $47,000. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DXCM. Royal Bank of Canada started coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday, May 17th. UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Finally, Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Trading Down 0.2 %

NASDAQ:DXCM opened at $130.53 on Thursday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The business has a fifty day moving average price of $133.10 and a 200-day moving average price of $123.99. The firm has a market capitalization of $51.91 billion, a price-to-earnings ratio of 84.21, a price-to-earnings-growth ratio of 2.22 and a beta of 1.23. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Sell-side analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Insiders have sold 186,641 shares of company stock worth $25,217,707 over the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.